Faeth Therapeutics, Inc.
NASDAQ:FTHBiotechnology
+$1.43 today
- Market cap
- $224.79M
- Beta
- -0.31
- P/E (TTM)
- -0.2
- EPS (TTM)
- -$34.65
Volume 0.33M
Average 0.12M
Returns on capital
Faeth Therapeutics, Inc. management
Start with the returns management earns on the capital it controls, then review the people, their trades, and growth quality.
Return Metrics
ROE, ROIC & ROA over time
ROE
-113.4%
avg -49.3%
ROIC
-110.9%
avg 1343.1%
ROA
-92.1%
avg -305.4%
Analysis
ROA is currently the strongest return metric at -92.1% versus its period average of -305.4%. 0 of 3 return metrics are above their quality threshold, which helps indicate how efficiently the company turns capital and assets into profit.
Leadership
Who runs the company?
Review the executive team, tenure, compensation, and ownership.
Management
Key executives, compensation & ownership
| Name | Title | Compensation | Age | Shares Owned | Ownership % |
|---|---|---|---|---|---|
Christopher Gerry | General Counsel & Secretary | USD 416.04K | 46 | 220.00K | 0.85% |
Josiah Craver | Senior Vice President of Finance, Principal Financial Officer & Principal Accounting Officer | USD 391.15K | — | 30.82K | 0.12% |
Benjamin Hopkins | Scientific Co-Founder | — | — | — | — |
Gregory J. Hannon | Scientific Co-Founder | — | — | — | — |
Lewis clayton Cantley | Scientific Co-Founder | — | 77 | — | — |
Scott W. Lowe | Scientific Co-Founder | — | — | — | — |
Siddhartha Mukherjee DPHIL | Scientific Co-Founder | — | 55 | — | — |
Simon Knott | Scientific Co-Founder | — | — | — | — |
Karen H. Vousden | Scientific Co-Founder & Director | — | 68 | 42.63K | 0.17% |
Anand Parikh | CEO, President & Chair | — | 40 | — | — |
Oliver Maddocks | Co-Founder & Chief Scientific Officer | — | — | — | — |
Compensation is shown in the reported currency; data updated Nov 18, 2026.
Ownership uses each executive's latest SEC Form 4 holding only when the full name maps to one reporting CIK; latest matched holding Sep 11, 2026.
Insider trading
Are insiders buying or selling?
Follow recent insider purchases and sales reported on Form 4.
Insider Trading
SEC Form 4 transactions — last 12 months
Buys
49
$2.53M
Sells
45
$2.28M
Net Transaction Value
+$250,415.94
Net buying
Most Active
MILLENNIUM MANAGEMENT LLC
51 transactions
Transactions sorted by date, descending.
| Type | |||
|---|---|---|---|
| Jul 1, 26Jul 1, 2026 | STEPHENSON BRIAN C Indirect | Buy | $14.5K$14,532.00 |
| Jul 1, 26Jul 1, 2026 | STEPHENSON BRIAN C Indirect | Buy | $103K$102,960.00 |
| Jun 30, 26Jun 30, 2026 | STEPHENSON BRIAN C Indirect | Buy | $39.1K$39,115.44 |
| Jun 30, 26Jun 30, 2026 | STEPHENSON BRIAN C Indirect | Buy | $43.8K$43,834.50 |
| Jun 30, 26Jun 30, 2026 | STEPHENSON BRIAN C Indirect | Buy | $106.3K$106,289.90 |
| Jun 29, 26Jun 29, 2026 | STEPHENSON BRIAN C Indirect | Buy | $19.4K$19,395.54 |
| Jun 26, 26Jun 26, 2026 | STEPHENSON BRIAN C Indirect | Buy | $34.7K$34,696.90 |
| Jun 26, 26Jun 26, 2026 | STEPHENSON BRIAN C Indirect | Buy | $13.7K$13,693.80 |
| Jun 26, 26Jun 26, 2026 | STEPHENSON BRIAN C Indirect | Buy | $2.6K$2,639.00 |
| Jun 26, 26Jun 26, 2026 | STEPHENSON BRIAN C Indirect | Buy | $104.9K$104,878.80 |
1–10 of 94
Summary
Insiders reported 49 buys worth $2.53M and 45 sells worth $2.28M over the last 12 months. That adds up to net buying of $250,415.94. MILLENNIUM MANAGEMENT LLC was the most active insider with 51 transactions.
Growth analysis
Is management growing the business?
Compare historical growth with analyst forecasts across revenue, earnings, and cash flow.
Competitors
Who does Faeth Therapeutics, Inc. compete with?
Open similar companies to compare how their management teams allocate capital.
Questions
Management questions
Common questions about FTH's management, answered from reported figures.
Who manages FTH?
Faeth Therapeutics, Inc. (FTH) lists 11 active executives. The top listed executive is Benjamin Hopkins, Scientific Co-Founder.
Are FTH insiders buying or selling?
Recent insider activity shows net buying of $56.18M.
Continue the stock analysis
Jump to another research area for this company.